Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 - Wiviott, Stephen D.; Braunwald, Eugene; Angiolillo, Dominick J.; Meisel, Simha; Dalby, Anthony J.; Verheugt, Freek W.A.; Goodman, Shaun G.; Corbalan, Ramon; Purdy, Drew A.; Murphy, Sabina A.; McCabe, Carolyn H.; Antman, Elliott M. (Circulation (New York, N.Y.), 2008)
Keywords: Administration, Oral; Aged; Associated diseases and complications; Biological and medical sciences; Blood and lymphatic vessels; Cardiology. Vascular system; Coronary Thrombosis - complications; Coronary Thrombosis - drug therapy; Diabetes Mellitus, Type 1 - complications; Diabetes Mellitus, Type 1 - drug therapy; Diabetes Mellitus, Type 2 - complications; Diabetes. Impaired glucose tolerance; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Female; Humans; Hypoglycemic Agents - administration & dosage; Insulin - administration & dosage; Kaplan-Meier Estimate; Male; Medical sciences; Middle Aged; Myocardial Infarction - complications; Myocardial Infarction - drug therapy; Myocardial Ischemia - complications; Myocardial Ischemia - drug therapy; Piperazines - administration & dosage; Platelet Aggregation Inhibitors - administration & dosage; Prasugrel Hydrochloride; Thiophenes - administration & dosage; Thrombolytic Therapy - methods; Ticlopidine - administration & dosage; Ticlopidine - analogs & derivatives; Treatment Outcome; Endocrinopathy; Human; Myocardial infarction; Prognosis; Diabetes mellitus; Oral administration; Cardiovascular disease; Anticoagulant; Instrumental dilatation; Coronary heart disease; Myocardial disease; Antiplatelet agent; platelets; Prasugrel; Platelet; Treatment; Antithrombotic agent; anticoagulants; angioplasty